Recently, Zhang et al. (189) found that TMP195, a selective class IIa HDAC inhibitor, protects the kidney by down-regulating TECs apoptosis and inflammation, suggesting that targeting class IIa HDACs may be a new treatment strategy for sepsis-AKI, which can avoid unexpected side effects of pan HDAC inhibitors. This evidence concerns the gene HDAC9 and acute kidney injury.